Statins help lower low-density lipoprotein cholesterol, or "bad" cholesterol.
KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
These studies had led to new cholesterol guidelines in the U.S. that suggested lowering low-density lipoprotein (LDL), or bad cholesterol, to extemely low levels.
Low-density lipoprotein, the bad cholesterol, carries cholesterol fat to the arteries, where it gets stored as plaque in the artery wall.
"Bad" cholesterol - or low density lipoprotein - can block arteries and cause heart disease.
Low-density lipoprotein (LDL) or bad cholesterol levels should be below 100, and high-density lipoprotein (HDL) should measure 35 or above.
The medicine worked incredibly well, lowering low-density lipoprotein (LDL), the bad cholesterol, by 70%.
FORBES: How A Mourning Entrepreneur And A Dogged Doctor Rescued A Rare Disease Drug
"I'm confused, " he says, because reducing low-density lipoprotein (LDL), or bad cholesterol, is such a cornerstone of cardiology.
But when Zetia was combined with a statin like Lipitor or Zocor, it lowered bad cholesterol, or low-density lipoprotein (LDL), more than anything else out there.
Both work by inhibiting an obscure molecule called the cholesterol ester transfer protein (CETP) that works indirectly to prevent HDL from being used to create low-density lipoprotein (LDL), the bad cholesterol.
Zetia (generically known as ezetimibe) lowers low-density lipoprotein (LDL), the bad cholesterol involved in causing heart attacks and strokes, but less so than existing drugs like Lipitor (generically known as atorvastatin), Crestor, from AstraZeneca, or simvastatin.
FORBES: Merck's Cholesterol Pill Win Is Already Drawing Fire
In Ridker's study, patients with high bad cholesterol, or low-density lipoprotein and high CRP had heart attacks, strokes or heart procedures 9.9% of the time compared with 4.9% of the time for patients where both risks were low.
Coronary artery disease begins when excess cholesterol particles, called low-density lipoprotein particles, become lodged in the artery wall over time and get chemically damaged, or oxidized (close-up diagram).
For patients at the highest risk of heart attack, the new guidelines suggest that "bad cholesterol, " or low-density lipoprotein (LDL), be reduced to 70 mg per deciliter--although the new guideline is optional.
Up until now, evidence for statins has been mainly in people with high "bad" cholesterol, properly known as low-density lipoprotein (LDL).
Schering and Merck have defended the drugs by pointing to the mountains of evidence that support the idea that lowering low-density lipoprotein, commonly known as LDL or "bad cholesterol, " prevents heart attacks.
Most of the time low-density lipoprotein (LDL), better known as "bad cholesterol, " sits around doing little.
The most common type of cholesterol problem is a high LDL (low density lipoprotein) which is usually best treated with a statin, of which there are at least four on the market.
应用推荐